Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A **multi-component nanoformulation** comprising lactoferrin, berberine, hyaluronic acid, and silk fibroin. Based on the provided context, this is best understood as an experimental **nanoparticle or biomaterial-based drug delivery construct** rather than an approved named drug product. Berberine is the cytotoxic small-molecule payload, while hyaluronic acid and lactoferrin are used as bioactive targeting and delivery components; silk fibroin functions as a structural biomaterial carrier. Mechanistically, the construct is intended to improve tumor-selective delivery and retention, with hyaluronic acid commonly used to engage CD44-enriched tumor cells, lactoferrin serving as a targeting and uptake-enhancing protein, and berberine providing anticancer activity through pleiotropic effects on proliferation and apoptosis pathways. No specific sponsor, brand name, or formal development program for the exact four-component combination was identified from the provided source excerpt.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lactoferrin + berberine + hyaluronic acid + silk fibroin.